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The sequences of the capsid genes of a human papillomavirus type 16 (HPV 16) DNA and an HPV 31 DNA were determined.
The HPV 16 DNA contained genes coding for the most variable HPV 16 capsid proteins yet identified (17 variable amino
acids). Three of six coding changes in the HPV 31 DNA occurred at positions equivalent to ones where variable amino
acids in HPV 16 have been observed. Variable amino acids in both viruses occurred predominantly in regions which showed
amino acid variation when closely related types of HPV were compared; thus, most of the factors which determined the
intratypic variation in the capsid proteins of the viruses described here were likely the same as those which determined
differences between the capsid proteins of different HPV types. q 1995 Academic Press, Inc.
Human papillomaviruses (HPVs) are a diverse group residing in different countries who have no known con-
of viruses associated with significant human diseases, tact with each other (8). The stability of HPV variants and
including laryngeal papillomatosis, genital warts, and the long-term presence of the common genotypes in all
cervical cancer (1 – 3). Papillomaviruses are classified by ethnic groups suggests that some of the factors involved
the nucleic acid sequences of their genomes. A papillo- in variant establishment for other groups of viruses, such
mavirus genotype has less than 90% nucleotide (nt) ho- as antigenic changes during infection of a single individ-
mology with other genotypes, while HPV DNAs with more ual and introduction of a single variant into an uninfected
than 98% nt homology are considered variants within a population, are not important for HPVs (9, 10). The pres-
genotype (4). More than 70 HPV genotypes have been ent study was undertaken to characterize better the fac-
identified and most genotypes are associated with spe- tors which were involved in establishing HPV variants
cific diseases (1). Naturally occurring variants of a num- by generating capsid sequences of naturally occurring
ber of the genotypes have been identified, and some variants of two closely related genotypes, HPV 16 and
have markedly different functional properties. For exam- HPV 31, and by analyzing these sequences in relation to
ple, the ability of variants of HPV type 16 (HPV 16) capsid the capsid sequences of the reference genotypes.
proteins to assemble into virion-like particles has been The specimen containing the variant HPV 16 DNA
mapped to a single amino acid residue, position 202 of (1194) was from a human immunodeficiency virus type
the L1 protein (5). 1 seropositive woman with cervical intraepithelial neo-
Papillomaviruses have likely been associated with hu- plasia grade III (CIN III) who lived in Zaire (11, 12). This
mans for at least 200,000 years, and all ethnic groups HPV 16 DNA was quite variable in previous limited se-
have likely been carriers of the common papillomavirus quencing experiments and thus was chosen for sequenc-
genotypes (e.g., HPV 16) since their point of origin (6, 7). ing of the full capsid region [the L2 and L1 open reading
During the association of HPVs with humans, numerous frames (ORFs)]. Four HPV 31 DNA-containing specimens
HPV variants have occurred and have become estab- (B60, L26, B46, and M52) were from women who lived in
lished naturally (7). These variants are stable since iden- the United States and who had CIN III, CIN III, CIN III,
tical variants have been found in unrelated individuals and CIN I, respectively. The HPV 31 DNAs were first
studied by amplifying a portion of the L1 ORF using the
The nucleotide sequence data reported in this paper have been polymerase chain reaction (PCR) and by partially se-
submitted to the GenBank nucleotide sequence database and have quencing the products using standard protocols (Tablebeen assigned the Accession Nos. U37217 and U37410.
1). Two samples (B60 and L26) contained DNA which1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (404) 639-0049. E-mail: JCI1@CIDDVD1.EM.CDC.GOV. was identical to the reference DNA (15, 16). The re-
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TABLE 1 and 0.8%, respectively; variants can differ by as much as
2% from the reference sequence.Variable Nucleotides in a Portion of the L1 ORF of HPV 31 DNAs
The 1194 variant of HPV 16 had 17 variable amino(nt 6195 through 6510)
acids in the capsid region and the capsid of the M52
Nucleotide variant of HPV 31 had 6 variable amino acids (Table 3).
The maximum number of variable amino acids previously
6238 6328 6350 6367 6372 6379 6409
reported in both capsid proteins of a single HPV 16 DNA
is 6; the maximum numbers of variable amino acids pre-Reference Ta G A C C A T
Sample viously reported in the individual HPV 16 L2 and L1 pro-
990b — A Gc T Ad — G teins are 4 and 6, respectively (20). Thus, 1194 DNA
B60 — — — — — — — coded for the most variable HPV 16 capsid thus far de-
L26 — — — — — — —
scribed. Furthermore, 12 of the amino acid replacementsB46 A — — T A G —
in 1194, 7 in the L2 protein, and 5 in the L1 proteinM52 — A G T A — —
had not been previously observed (Table 3). The variable
a The region of HPV 31 DNA from nt 6161 through 6574 was amplified amino acids in the M52 L1 protein have been reported
using 5*-ACTGGCTTTGGTGCTATGGACTTT-3* and 5*-GTACTGCGT- previously, but the 4 variable amino acids in the M52 L2
GTAGTATCAACAACAG-3* as previously described (9). DNA for se-
protein are the first reported for an HPV 31 L2 (12). Ofquencing was prepared by first amplifying DNA in two reactions in
the variable amino acid positions found in 1194 and M52,which one of these primers was biotinylated. Single-strand DNA was
then prepared with streptavidin-coated magnetic beads using a stan- only HPV 16 L1 amino acid residue 266 (267 for HPV 31)
dard protocol and both strands were sequenced according to the is conserved in the closely related reference genotypes
Sequenase version 2.0 protocol using the nonbiotinylated primer to HPV 16, HPV 31, and HPV 35, and this residue is often
prime the sequencing reactions (Dynal A. S., Great Neck, NY) (United
found to be different in variants (8, 12, 22).States Biochemical, Cleveland, OH). The termination products were
Both of the variable amino acids in the L1 protein oflabeled with 35S-dATP. Both the Nucaln program (13) and the GCG
program (14) were used in nt sequence data analysis. M52 and the variable amino acid at position 377 of the
b This previously sequenced sample is included for comparison (12). L2 protein of M52 occurred at positions equivalent to the
c A at position 6350 results in a codon for threonine at L1 amino positions where variable amino acids had been observed
acid residue 267, and G at position 6350 results in a codon for alanine.
in the 1194 variant or in previous studies of other HPV 16d C at position 6372 results in a codon for threonine at L1 amino acid
variants (20). The remaining three variable amino acids inresidue 274, and A at position 6372 results in a codon for asparagine.
M52 occurred at positions no more than eight amino
acids from the positions of variable amino acids ob-
served in the 1194 variant. Thus, the location of the vari-maining two samples (B46 and M52) each contained a
variant HPV 31 DNA. The DNA in sample M52 was cho- able amino acids in M52 compared to the location of
variable amino acids in HPV 16 variants indicates thatsen for further sequencing since it coded for two variable
amino acids in this region. M52 and HPV 16 variants likely became established in
similar selective conditions.DNAs containing the entire L2 and L1 ORFs were am-
plified by the PCR from either 1194 or M52 and se- The location of variable amino acids observed in 1194
and M52 and in variants from other studies did not corre-quenced. Comparison of the nt sequence of the 1194
DNA with the reference sequence showed that 1194 had late well with hydrophilic or hydrophobic regions of the
capsid (data not shown) (20). However, the positions of44 nt differences (Table 2). Corrections which have been
made in the reference HPV 16 sequence were consid- variable amino acids and the regions of variability in the
capsid proteins determined by comparing closely relatedered when defining a nt as variable, but, to facilitate
comparison with other data, the nt numbers in Table 2 genotypes were correlated. This comparison was carried
out by first determining the similarity of the amino acidrefer to the original sequence (GenBank Accession No.
K02718) (5, 17, 18, 19). Only 8 of the 44 nt changes in sequences of the L2 and L1 proteins of closely related
genotypes of HPV [types 16, 31, 33, 35, 52, and 58 (6 ofthe 1194 DNA had been previously observed, clearly
demonstrating that the 1194 DNA was not closely related the 7 Group A9 HPVs)] by using standard algorithms (Fig.
1) (14, 22, 23). Note that if the average similarity for bothto any previously described HPV 16 variant (5, 20). Com-
parison of the nt sequence of the M52 DNA with the capsid proteins had been used as a cutoff (score, 0.7),
regions four and seven of the L1 protein would havereference sequence showed that M52 had 24 nt differ-
ences (Table 2) (15). The DNA in M52 was not closely fallen below the cutoff. The limits of the regions identified
in Fig. 1 were then determined for the purposes of thisrelated to a previously described HPV 31 DNA, HPV 31b,
since only 1 of the 3 changes occurring in the L2 and L1 study by inspection of an alignment of the HPV 16 and
HPV 31 proteins. When the positions of variable aminoORFs of HPV 31b also occurred in the DNA in M52 (C
at position 5921) (21; Laimonis A. Laimins, personal com- acids were compared with the variable regions of the
HPV 16 and HPV 31 proteins, the variable amino acidsmunication). Note that the capsid sequences of 1194 and
M52 DNAs differed from the reference sequences by 1.5 were found to have occurred predominantly in the re-
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TABLE 2 TABLE 3
Variable Nucleotides in the L1 and L2 ORFs of DNAs Variable Amino Acids in the L1 and L2 Proteins
of 1194 (HPV 16) and M52 (HPV 31)from 1194 (HPV 16) and M52 (HPV 31)
1194a (HPV 16) M52 (HPV 31)b Equivalent
HPV 16 Amino acid
Sample ORFa Position position changeORF Position nt ORF Position nt ORF Position nt
L2 4279 C L1 5696 A L2 4329 G 1194 L2 122 — S to P
L2 269 — S to Pb4426 T 5862 T 4359 A
4516 G 5909 C 4513 A L2 334 — D to N
L2 352 — T to P4543 G 6163 A 4544 G
4555 G 6178 C 4632 G L2 378 — S to Fb
L2 385 — V to I4598 C 6240 G 4644 C
4642 A 6245 C 4665 A L2 420 — I to T
L2 424 — A to T4723 T 6314 G 4899 A
4852 T 6432 G 4980 G L2 443 — A to G
4885 G 6480 C 4999 T
M52 L2 115 115 V to I4936 A 6557 T 5121 A
L2 125 125 H to R5039 C 6693 C 5299 T
L2 270 277 I to M5140 A 6719 A 5427 T
L2 377 385 V to L5234 A 6852 T L1 5920 G
5257 G 6863 T 5921 C 1194 L1 76 — H to Y
5288 C 6968 T 6019 G L1 176 — T to N
5308 C 6992 A 6085 T L1 181 — N to Tb
5367 T 7049 G 6328 A L1 202 — H to Db
5377 A 7058 T 6350 G L1 266 — T to Ab
5387 A 6367 T L1 282 — S to P
5401 C 6372 A L1 353 — T to P
5485 T 6586 G L1 474 — L to F
5493 C 6796 A
M52 L1 267 266 T to Ab5504 A 6817 A
L1 274 273 T to Nb5562 G
a The consensus start codon (nt 5637) of the L1 ORF was used fora The capsid region of the HPV 16 DNA from 1194 was amplified by
analysis of the amino acids coded for by the HPV 16 DNA. The HPVthe PCR using primers that defined a 3253-bp product extending from
16 sequence used for identifying amino acid changes is the originalnt 4004 through 7256 (5*-GCAGCCTCTGCGTTTAG-3* and 5*-CCATAC-
sequence modified by subsequent studies (5, 17, 19), and the HPV 31ATACAAACACACATACAACTT-3*). The product was cloned into
sequence is the original sequencing work (15).pT7Blue according to the manufacturer’s instructions (Novagen, Madi-
b This amino acid change has previously been observed (5, 12, 20).son, WI) and sequenced by standard protocols similar to those listed
in Table 1. Both strands of HPV DNA were sequenced by using a series
of primers that bound at approximately 300-base intervals to each DNA
gions of variability (Fig. 2). This result indicated that thestrand. A sequence from nt 4235 through 7154 was thus determined.
Any nt in the clone which differed from the reference sequence was factors associated with the establishment of variable
verified in the bulk 3253-bp product, ensuring that the observed amino acids in the capsid proteins of variants of HPV
changes were not due to PCR-generated errors (8). For simplicity, nt 16 and HPV 31 were largely the same factors as those
numbers shown refer to the original report of the HPV 16 sequence
associated with the establishment of capsids of the dif-even though errors have been subsequently found (GenBank Acces-
ferent Group A genotypes of HPV.sion No. K02718) (5, 17, 19).
b The capsid region of HPV 31 DNA from M52 was amplified using However, there were two observations that indicated
HPV 16 primers that cross-hybridized with HPV 31 and defined a 3198- that the factors associated with the establishment of vari-
bp product extending from nt 3972 through 7170 (5*-GCAACCTCTCCA- ants were not precisely the same as those associated
TTACG-3* and 5*-GCATACATAAACATACATATACCATAT-3*). The prod-
with the establishment of different genotypes. First, vari-uct of the first PCR reaction was used as template in a set of PCRs
able amino acids occurred outside the variable regionsdesigned to generate three overlapping DNA sequencing templates.
The three primer sets were (1) 5*-GTAATTCATACACATGCATC-3* and for the L1 protein but not for the L2 protein. Second, if
5*-CTACTATATCTAACAGTGTTCCTACG-3*, (2) 5*-ATTGATCCAACG- one assessed the amino acid variability of L2 proteins
TTTCTTAGTGCT-3* and 5*-CTATTAGAGTTTTCAGTGTCAT-3*, and (3) relative to L1 proteins by comparing variants of HPV 16,
5*-ACAGTAGGCCATCCATATTATTCC-3* and 5*-ACACACACATATACA-
the two proteins were equally variable [15 variable aminoATACAGCACAA-3*. The primer sets amplified regions of 1006, 1067,
and 1451 bp starting at nt 4032, 4867, and 5681, respectively. Both
strands of these three products were sequenced by using a series of
primers that bound at approximately 300-base intervals to each DNA kit and analyzed with a 373 DNA Sequencer and associated software
strand. Sequencing of total PCR products using similar procedures has according to the manufacturer’s instructions (Applied Biosystems, Fos-
been shown to be insensitive to PCR-generated errors (8). Double- ter City, CA). A sequence from nt 4171 through 7066 was thus deter-
strand sequencing reactions were done with the ABI Cycle Sequencing mined.
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FIG. 1. Similarity of the capsid proteins of HPV 16, 31, 33, 35, 52, and 58. The predicted amino acid sequences of the capsid proteins of these
HPV genotypes were analyzed for similarities by using the Pileup and Plotsimilarity algorithms (14). The Pileup program was run with default
parameters and the Plotsimilarity program was run with the /IDE option and a 20-amino-acid window.
acid positions in both HPV 16 L2 and HPV 16 L1 (Fig. that variant 1194 and variant M52 became established
because they could escape neutralization by antibodies2)]. However, comparison of different closely related ref-
erence genotypes, such as HPV 16 and HPV 31, showed to other variants as a result of the variable amino acids
which they have in the L2 protein and/or the L1 protein.that L2 is much more variable than L1. These observa-
tions indicate that the long-term evolution of HPV capsid One should note that the long, continuous association
of HPVs with humans might allow the establishment ofproteins does involve some factors which are different
from those determining the generation of variants. variants which could only partially evade immunity to
other variants.While the establishment of a variant HPV will obviously
depend on its total fitness, as determined by its total nt A comparison of the positions of variable nts with the
positions of variable amino acids in L2 was also useful.sequence, one objective of the present study was to
consider possible roles for variation in HPV capsids in A tabulation of the L2 nt and amino acid variation from
1194 and from two published studies gave 12 codingestablishing variants. Since introduction of an HPV 16
variant into a previously uninfected population is unlikely, changes in 19 total nt changes in the carboxy-terminal
one-third of L2 and only 3 coding changes in 18 total ntthe probability that a papillomavirus with a different
amino acid(s) in its capsid protein(s) will become estab- changes in the remaining two-thirds of L2 (one-tailed
Fischer’s Exact Test, P  0.005) (5, 20). It is likely thatlished should be determined by how that amino acid(s)
affects functional properties of the capsid, such as virion many variants with coding changes in the amino-terminal
two-thirds of L2 have occurred, but have not becomeassembly and stability, immune recognition of the capsid,
receptor binding, and virion uncoating. Previous studies established because the coding changes occurred in
regions which were functionally constrained (e.g., re-have mapped DNA binding domains and nuclear local-
ization signals, both of which are presumably essential gions involved in intersubunit interactions).
Work by Pushko and co-workers is consistent withto virion assembly, to the first 12 amino acids of L2 and
to the region between 484 and 504 of L1, respectively as many as 40% of HPV 16 DNAs being recombinants
between L2 ORFs identical to reference HPV 16 and(25, 26). Variable amino acids have not been observed
at these locations. Antibody reactivity has been the sub- variant L1 ORFs (20). No evidence for recombination was
found in either of the capsid regions reported here.ject of a number of studies, and regions involved in anti-
body binding have been identified in both the L2 protein The worldwide distribution of viruses identical to or
closely related to the variants described here would beand the L1 protein (27, 28, 29, 30, 31). It is possible
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FIG. 2. Locations of HPV 16 and 31 variable amino acids in the capsid proteins of variant viruses compared to variable regions in the capsid
proteins identified by comparison of reference HPV 16 and 31 proteins. The limits of the variable regions identified in Fig. 1 were determined by
inspection of an alignment of the L2 and L1 protein sequences from HPV 16 and 31 and are indicated by the thickened portions of the lines. The
locations of the HPV 16 variable amino acids and of the HPV 31 variable amino acids listed in Table 3, as well as the locations of previously
identified variable amino acids, are marked (5, 20). There are no significant insertions/deletions in the HPV 16 capsid proteins relative to the HPV
31 capsid proteins, so that the position of variable amino acids of both genotypes can be accurately placed on a single figure. Some studies in
which only portions of the capsid proteins of variants were sequenced were not included because the intent was to compare the distribution of
variable amino acids within the entire capsid proteins (e.g., 22).
interesting to determine. Viruses very closely related to sembled from 1194 proteins are the same as those as-
sembled from reference proteins. Such studies might1194 have recently been observed in approximately 10%
of the HPV 16 infections in some populations in the also provide additional information about the factors
which were important in determining the establishmentUnited States, indicating that this variant is stable and
widely distributed (Steve Jenison, personal communica- of this papillomavirus variant.
tion). In addition, previously sequenced HPV 16 variants
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